2025
Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, Singh R, Dvory-Sobol H, Ogbuagu O, Segal-Maurer S, Molina J, Rhee M, Callebaut C. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal Of Infectious Diseases 2025, 231: 1239-1245. PMID: 39873394, DOI: 10.1093/infdis/jiaf050.Peer-Reviewed Original ResearchOptimized background regimenHIV-1HIV-1 RNA <HIV-1 RNA suppressionTreatment-experienced peopleTandem liquid chromatography/mass spectrometryFirst-in-class inhibitorResistant to 2HIV-1 capsidBackground regimenTreatment-experiencedVirological failureLenacapavirRNA suppressionDrug classesDrug measurementsResistance assaysMonotherapyPWHLiquid chromatography/mass spectrometryTreatmentDrugResistance analysisResuppressionYears
2024
Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome
Wang S, Xiong Y, Jang M, Park K, Donahue M, Velez J, Jin J, Jiang Y. Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome. Molecular Therapy 2024, 32: 2662-2675. PMID: 38796700, PMCID: PMC11405540, DOI: 10.1016/j.ymthe.2024.05.034.Peer-Reviewed Original ResearchPrader-Willi syndromeEpigenetic therapyMouse modelChromosome 15q11-q13 regionPWS mouse modelFirst-in-class inhibitorEfficacy of oral administrationPoor oral bioavailabilityPotential epigenetic therapiesReduction of H3K9me2Paternally expressed genesOral bioavailabilityIntraperitoneal routeOral administrationPerinatal lethalityTherapeutic benefitBrain penetrationMolecular efficacyPatient fibroblastsEpigenetic modulationGenomic disordersMaternal chromosomeBrain permeabilityLiver tissueCandidate genes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply